

浙江省科学技术奖公示信息表（单位提名）

提名奖项：科学技术进步奖

成果名称	靶向前列腺肿瘤能量代谢精准诊疗关键技术创新及应用
提名等级	二等奖
提名书相关内容	<p>代表性论文目录：</p> <ol style="list-style-type: none">1. Shuangya Chen[#], Jisheng Ma[#], Yunbei Xiao[#], Dongyan Zhou, Ping He, Yajing Chen, Xiaolu Zheng, Hui Lin, Feng Qiu, Yuying Yuan, Jiaben Zhong, Xiaokun Li*, Xuebo Pan*, Zhiyuan Fang*, Cong Wang*. RNA interference against ATP as a gene therapy approach for prostate cancer. <i>Mol. Pharmaceutics</i> 2023, 20, 5214–5225.2. Zhichao Fan[#], Jisheng Ma[#], Xuebo Pan[#], Liangcai Zhao, Yuying Wu, Hui Lin, Yidan Zhao, Haowei Jiang, Tingting Pan, Xiaokun Li*, Fen Wang*, Cong Wang*. Crosstalk of FGFR1 signaling and choline metabolism promotes cell proliferation and survival in prostate cancer cells. <i>Int J Cancer</i>. 2022 May 1;150(9):1525-1536.3. Cong Wang[#], Yuepeng Ke[#], Shaoyou Liu[#], Sharon Pan, Ziying Liu, Hui Zhang, Zhichao Fan, Changyi Zhou, Junchen Liu, and Fen Wang*. Ectopic fibroblast growth factor receptor 1 promotes inflammation via augmenting nuclear factor-κB signaling in prostate cancer cells. <i>J. Biol. Chem.</i> 2018 Sep 21;293(38):14839-14849.4. Zhiyuan Fang[#], Yu Wang[#], Hao Li[#], Shuaishuai Yu, Ziying Liu, Zhichao Fan, Xiaomin Chen, Yuying Wu, Xuebo Pan*, Xiaokun Li*, Cong Wang*. Combination treatment of citral potentiates the efficacy of hyperthermic intraperitonealchemoperfusion with pirarubicin for colorectal cancer. <i>Mol Pharm</i>. 2017 Oct 2;14 (10):3588-3597.5. Yingying Pan, Baile Wang, Jujia Zheng, Rongrong Xiong, Zhichao Fan, Yanna Ye, Saisai Zhang, Qinyao Li, Fanghua Gong, Chaoming Wu, Zhuofeng Lin, Xiaokun Li*, Xuebo Pan*. Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner. <i>J Cell Mol Med</i>. 2019 Feb;23(2):1059-1071.6. Ping He, Shuting Zhong, Shuaijun Lin, Zhiyan Xia, Liqing Wang, Yuhe Han, Di Xu, Shuping Hu, Xiaokun Li, Peijun Li*, Cong Wang*. FGF9 is required for Purkinje cell development and function in the cerebellum. <i>iScience</i>. 2024 Jan 26;27(2):109039.

	<p>7. Cong Wang^{#*}, Yuelong Li[#], Hao Li[#], Yali Zhang, Zhangguo Ying, Xuye Wang, Tingting Zhang, Wenshu Zhang, Zhichao Fan, Xiaokun Li*, Jisheng Ma*, Xuebo Pan*. Disruption of FGF signaling ameliorates inflammatory response in hepatic stellate cells. <i>Front. Cell Dev. Biol.</i>, 22 July 2020.</p> <p>8. Wang C*, Liu Z, Ke Y, Wang F*. Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer. <i>Front Genet.</i> 2019 Jan 30;10:12.</p> <p>9. Hainiao Xiao, Zhigang Wu, Qinquan Wang, Chaofeng Zhou, Feng Lu, Yunbei Xiao. Chalcone Derivatives Suppress Proliferation and Migration of Castration-resistant Prostate Cancer Cells Through FAK-mediated DNA Damage. <i>Anticancer Res.</i> 2023 Jan;43(1):389-403.</p>
主要完成人	王聪, 排名 1, 副研究员, 温州医科大学; 潘薛波, 排名 2, 副教授, 温州医科大学; 马吉胜, 排名 3, 研究员, 温州医科大学; 萧云备, 排名 4, 主治医师, 温州医科大学附属第一医院; 龚方华, 排名 5, 副教授, 温州医科大学; 胡淑平, 排名 6, 副教授, 温州医科大学
主要完成单位	1. 温州医科大学 2. 温州医科大学附属第一医院
提名单位	温州市人民政府
提名意见	<p>本项目揭示代谢模式转变对前列腺肿瘤发生发展的影响, 为前列腺肿瘤精准诊断和治疗提供了新的思路; 自主创新构建溶瘤病毒抑制肿瘤细胞能量生成, 具有稳定的生物学活性及高效的肿瘤抑制效应; 孵化出多个靶向肿瘤生物治疗的相关应用产品, 代表性论文被国际顶级期刊多次引用, 为我市生物医药发展作出了重要贡献。</p> <p>提名该成果为省科学技术进步奖二等奖。</p>